A continuous glucose monitoring device as a valuable tool for supporting diabetes care in haemodialysis patients: A qualitative interview study

Continuous glucose monitoring (CGM) potentially supports diabetes care in dialysis patients. This qualitative study explores the use of CGM in individuals with type 1 diabetes and those with insulin-treated type 2 diabetes undergoing haemodialysis (HD). Twelve HD patients participated in face-to-face interviews between June 2022 and June 2023 at two dialysis wards in Denmark. Data were analysed using reflective thematic analysis. The study was reported in accordance with the Consolidated Criteria for Reporting Qualitative Research (COREQ) guidelines. Six themes emerged: (1) CGM as a tool for managing both hypo- and hyperglycaemia; (2) CGM promotes well-considered choices; (3) CGM reduces practical barriers in diabetes management; (4) CGM enhances security and confidence in diabetes management; (5) Guidance from healthcare professionals maximises the benefits of CGM; and (6) Mixed opinions on CGM alarms. In conclusion, CGM shows promise in improving diabetes management and daily life for HD patients. However, further research is needed to identify optimal candidates, assess cost-effectiveness, and explore healthcare perspectives on CGM use in this population.